Guillain-Barré Syndrome after Septicemia following Clozapine-Induced Agranulocytosis

We report the case of a patient with schizophrenia, who experienced agranulocytosis during clozapine treatment, followed by bronchopulmonal infection and Guillain-Barré syndrome. The case was recorded within the German surveillance project ”drug safety in psychiatry” (AMSP) [2].

References

• 1 Buchwald B, Ahangari R, Weishaupt A, Toyka K V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome.  Ann Neurol. 2002;  51 667-669
• 2 Grohmann R, Engel R R, Ruther E, Hippius H. The AMSP drug safety program: methods and global results.  Pharmacopsychiatry. 2004;  37 (Suppl 1) 4-11
• 3 Hinze-Selch D, Becker E W, Stein G M, Berg P A, Mullington J, Holsboer F, Pollmächer T. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients.  Neuropsychopharmacol. 1998;  19 114-122
• 4 Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmächter T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight.  Psychopharmacology. 2000;  149 163-169
• 5 Löffler S, Fehsel K, Henning U, Fischer J, Agelink M, Kolb-Bachofen V, Klimke A. Increased apoptosis of neutrophils in a case of clozapine-induced agranulocytosis - a case report.  Pharmacopsychiatry. 2003;  36 37-41
• 6 Toyka K V. Eighty three years of Guillain-Barre syndrome: clinical and immunopathologic aspects, current and future treatments.  Rev Neurol (Paris). 1999;  155 849-56
• 7 Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes.  Lancet Infect Dis. 2001;  1 29-37